LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 174

Search options

  1. Article ; Online: Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma.

    Torres, Harrys A / Mustafayev, Khalis / Nastoupil, Loretta J / Shelburne, Samuel A

    Lancet (London, England)

    2024  Volume 403, Issue 10434, Page(s) 1372–1373

    MeSH term(s) Humans ; Hepatitis B/drug therapy ; Lymphoma/drug therapy ; Hepatitis B virus ; Antiviral Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Rituximab/adverse effects
    Chemical Substances Antiviral Agents ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2024-04-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(24)00397-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Hyperphosphorylation of the Group A Streptococcal Control of Virulence Regulator Increases Promoter Occupancy Specifically at Virulence Factor-Encoding Genes.

    Horstmann, Nicola / Tran, Chau Nguyen / Flores, Anthony R / Shelburne, Samuel A

    Journal of bacteriology

    2023  Volume 205, Issue 6, Page(s) e0011823

    Abstract: ... ...

    Abstract The
    MeSH term(s) Humans ; Virulence ; Virulence Factors/genetics ; Virulence Factors/metabolism ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Histidine Kinase/metabolism ; Streptococcus pyogenes/metabolism ; Phosphoric Monoester Hydrolases/metabolism ; Streptococcal Infections/microbiology ; Gene Expression Regulation, Bacterial
    Chemical Substances Virulence Factors ; Bacterial Proteins ; Histidine Kinase (EC 2.7.13.1) ; Phosphoric Monoester Hydrolases (EC 3.1.3.2)
    Language English
    Publishing date 2023-06-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2968-3
    ISSN 1098-5530 ; 0021-9193
    ISSN (online) 1098-5530
    ISSN 0021-9193
    DOI 10.1128/jb.00118-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Emergent

    Odo, Chioma M / Vega, Luis A / Mukherjee, Piyali / DebRoy, Sruti / Flores, Anthony R / Shelburne, Samuel A

    bioRxiv : the preprint server for biology

    2024  

    Abstract: The major gram-positive pathogen group ... ...

    Abstract The major gram-positive pathogen group A
    Language English
    Publishing date 2024-04-10
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.04.09.588776
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Identification of a novel CG307 sub-clade in third-generation-cephalosporin-resistant

    Selvaraj Anand, Selvalakshmi / Wu, Chin-Ting / Bremer, Jordan / Bhatti, Micah / Treangen, Todd J / Kalia, Awdhesh / Shelburne, Samuel A / Shropshire, William C

    Microbial genomics

    2024  Volume 10, Issue 2

    Abstract: Despite the notable clinical impact, recent molecular epidemiology regarding third-generation-cephalosporin-resistant (3GC-R) ...

    Abstract Despite the notable clinical impact, recent molecular epidemiology regarding third-generation-cephalosporin-resistant (3GC-R)
    MeSH term(s) Humans ; United States/epidemiology ; Klebsiella pneumoniae/genetics ; Bacteremia/epidemiology ; Comparative Genomic Hybridization ; Databases, Factual ; Cephalosporins
    Chemical Substances Cephalosporins
    Language English
    Publishing date 2024-02-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 2835258-0
    ISSN 2057-5858 ; 2057-5858
    ISSN (online) 2057-5858
    ISSN 2057-5858
    DOI 10.1099/mgen.0.001201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Toward an Understanding of Group A Streptococcal Transmission Dynamics Using National-level Surveillance.

    Flores, Anthony R / Shelburne, Samuel A

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2019  Volume 70, Issue 7, Page(s) 1482–1483

    MeSH term(s) Humans ; Population Surveillance ; Streptococcal Infections/epidemiology ; Streptococcus pyogenes ; United States
    Language English
    Publishing date 2019-08-13
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciz718
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: In vitro

    Gerges, Bahgat / Rosenblatt, Joel / Truong, Y-Lan / Jiang, Ying / Shelburne, Samuel A / Chaftari, Anne-Marie / Hachem, Ray / Raad, Issam

    JAC-antimicrobial resistance

    2024  Volume 6, Issue 2, Page(s) dlae060

    Abstract: Background: Taniborbactam is a β-lactamase inhibitor that, when combined with cefepime, may offer a potential treatment option for patients with serious and resistant Gram-negative bacterial (GNB) pathogens.: Objectives: This study evaluated : ... ...

    Abstract Background: Taniborbactam is a β-lactamase inhibitor that, when combined with cefepime, may offer a potential treatment option for patients with serious and resistant Gram-negative bacterial (GNB) pathogens.
    Objectives: This study evaluated
    Methods: A total of 270 GNB pathogens (2019-23) isolated from patients with cancer were tested against cefepime/taniborbactam and comparator agents commonly used for these patients. CLSI-approved broth microdilution methods were used. MIC
    Results: Cefepime/taniborbactam showed highly potent activity against tested Enterobacterales, including isolates producing ESBLs and carbapenem-resistant Enterobacterales. At a provisional breakpoint of ≤16/4 mg/L, cefepime/taniborbactam inhibited most tested species of GNB pathogens, with overall 98.9% susceptibility, which was significantly (
    Conclusions: Our results showed that taniborbactam in combination with cefepime improved
    Language English
    Publishing date 2024-04-10
    Publishing country England
    Document type Journal Article
    ISSN 2632-1823
    ISSN (online) 2632-1823
    DOI 10.1093/jacamr/dlae060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The

    Gerges, Bahgat / Rolston, Kenneth / Shelburne, Samuel A / Rosenblatt, Joel / Prince, Randall / Raad, Issam

    JAC-antimicrobial resistance

    2023  Volume 5, Issue 2, Page(s) dlad034

    Abstract: Background: Fluoroquinolones are used for infection prevention in high-risk patients with haematological malignancies. Fluoroquinolones are active against many Gram-negative bacilli (GNB) but are less active against Gram-positive organisms. We evaluated ...

    Abstract Background: Fluoroquinolones are used for infection prevention in high-risk patients with haematological malignancies. Fluoroquinolones are active against many Gram-negative bacilli (GNB) but are less active against Gram-positive organisms. We evaluated the
    Methods: Antimicrobial susceptibility testing and time-kill studies were performed using CLSI-approved methodology and interpretive criteria for 350 Gram-positive organisms and 210 GNB that had been recently isolated from patients with cancer.
    Results: Delafloxacin was more active than ciprofloxacin and levofloxacin against
    Conclusions: Delafloxacin is more active than ciprofloxacin and levofloxacin against
    Language English
    Publishing date 2023-03-27
    Publishing country England
    Document type Journal Article
    ISSN 2632-1823
    ISSN (online) 2632-1823
    DOI 10.1093/jacamr/dlad034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Streptococcus pyogenes With Reduced Susceptibility to β-Lactams: How Big an Alarm Bell?

    Hanage, William P / Shelburne, Samuel A

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2019  Volume 71, Issue 1, Page(s) 205–206

    MeSH term(s) Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Humans ; Microbial Sensitivity Tests ; Mutation ; Streptococcus pyogenes/genetics ; beta-Lactams/pharmacology
    Chemical Substances Anti-Bacterial Agents ; beta-Lactams
    Language English
    Publishing date 2019-11-18
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciz1006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: In vitro

    Rolston, Kenneth / Gerges, Bahgat / Nesher, Lior / Shelburne, Samuel A / Prince, Randall / Raad, Issam

    JAC-antimicrobial resistance

    2023  Volume 5, Issue 2, Page(s) dlad020

    Abstract: Background: Bacterial infections are common in patients with cancer, and many bacteria have developed resistance to currently used antibiotics.: Objectives: We evaluated the : Methods: Antimicrobial susceptibility testing was performed using CLSI- ... ...

    Abstract Background: Bacterial infections are common in patients with cancer, and many bacteria have developed resistance to currently used antibiotics.
    Objectives: We evaluated the
    Methods: Antimicrobial susceptibility testing was performed using CLSI-approved methodology and interpretive criteria for 255 Gram-positive and 310 Gram-negative bacteria. MIC and susceptibility percentage were calculated according to CLSI and FDA breakpoints when available.
    Results: Eravacycline had potent activity against most Gram-positive bacteria, including MRSA. Of 80 Gram-positive isolates with available breakpoints, 74 (92.5%) were susceptible to eravacycline. Eravacycline had potent activity against most Enterobacterales, including ESBL-producing organisms. Of 230 Gram-negative isolates with available breakpoints, 201 (87.4%) were susceptible to eravacycline. Eravacycline had the best activity among comparators against carbapenem-resistant Enterobacterales, with 83% susceptibility. Eravacycline was also active against many non-fermenting Gram-negative bacteria, with the lowest MIC
    Conclusions: Eravacycline was active against many clinically significant bacteria isolated from patients with cancer, including MRSA, carbapenem-resistant Enterobacterales, and non-fermenting Gram-negative bacilli. Eravacycline might play an important role in the treatment of bacterial infections in patients with cancer, and additional clinical evaluation is warranted.
    Language English
    Publishing date 2023-03-02
    Publishing country England
    Document type Journal Article
    ISSN 2632-1823
    ISSN (online) 2632-1823
    DOI 10.1093/jacamr/dlad020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185.

    Kawai, Akito / Shropshire, William C / Suzuki, Masahiro / Borjan, Jovan / Aitken, Samuel L / Bachman, William C / McElheny, Christi L / Bhatti, Micah M / Shields, Ryan K / Shelburne, Samuel A / Doi, Yohei

    mBio

    2024  Volume 15, Issue 2, Page(s) e0287423

    Abstract: β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in ... ...

    Abstract β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an
    MeSH term(s) Humans ; Ceftazidime/pharmacology ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Cephalosporins/pharmacology ; Drug Combinations ; Cefiderocol ; beta-Lactamases/metabolism ; Escherichia coli/metabolism ; Microbial Sensitivity Tests ; Azabicyclo Compounds
    Chemical Substances avibactam, ceftazidime drug combination ; Ceftazidime (9M416Z9QNR) ; Anti-Bacterial Agents ; avibactam (7352665165) ; Cephalosporins ; Drug Combinations ; Cefiderocol (SZ34OMG6E8) ; beta-Lactamases (EC 3.5.2.6) ; Azabicyclo Compounds
    Language English
    Publishing date 2024-01-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2557172-2
    ISSN 2150-7511 ; 2161-2129
    ISSN (online) 2150-7511
    ISSN 2161-2129
    DOI 10.1128/mbio.02874-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top